Exelixis
EXEL
#1620
Rank
A$16.42 B
Marketcap
$58.70
Share price
-0.38%
Change (1 day)
61.52%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): $0.43

According to Exelixis's latest financial reports the company's current EPS (TTM) is $0.45. In 2022 the company made an earnings per share (EPS) of $0.91 a decrease over its 2021 EPS that were of $1.18.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$0.43-52.92%
2022$0.91-22.97%
2021$1.18100%
2020$0.59-65.09%
2019$1.70-53.91%
2018$3.68333.96%
2017$0.85-260.61%
2016-$0.53-58.75%
2015-$1.28-42.45%
2014-$2.225.3%
2013-$2.1143.48%
2012-$1.47-264.29%
2011$0.90-165.88%
2010-$1.36-32.54%
2009-$2.02-17.65%
2008-$2.4575.86%
2007-$1.39-25.64%
2006-$1.878.33%
2005-$1.73-42.86%
2004-$3.0230.34%
2003-$2.32-5.23%
2002-$2.45-0.65%
2001-$2.46-51.88%
2000-$5.12

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$5.60 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
$5.09 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
$2.91 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$6.35 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
$22.63 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
$22.53 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
$2.97 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-$15.99-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-$1.34-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA